Drug Profile
KN 004
Alternative Names: KN-004Latest Information Update: 13 Dec 2018
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Alphamab; CITIC Medical and Health Group
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Dec 2018 Discontinued - Preclinical for Cancer in China (unspecified route)
- 07 May 2015 Preclinical trials in Cancer in China (unspecified route)